close read more
Press release

Servier and the Autonomous University of Barcelona collaborate to accelerate research into Parkinson’s disease


Servier and the Autonomous University of Barcelona collaborate to accelerate research into Parkinson’s disease

Paris (France) and Barcelone (Spain), June, 30 2020 – Servier, an international independent pharmaceutical company, and the Autonomous University of Barcelona (UAB), have signed a partnership agreement to speed up research into Parkinson’s disease, using a new method for small-molecule screening developed by Prof Salvador Ventura, PhD, group leader at the Institute of Biotechnology and Biomedicine (IBB) and at the Biochemistry and Molecular Biology Department at the UAB.


Within the framework of this agreement, scientists from Servier will collaborate with Prof Ventura’s teams to further develop and identify chemical series capable of neutralizing the pathogenicity of α-synuclein, a protein which is of major importance, not only in Parkinson’s disease, but also in several other neurodegenerative diseases.

“The discovery of new drugs to treat neurodegenerative and neuropsychiatric diseases is a key focus for Servier as there remain many unmet needs for patients with these pathologies, “ stated Ross Jeggo, Director of Neuropsychiatric Research for the Servier Group. “Thanks to Prof Ventura’s high-level expertise, this collaboration represents an opportunity for Servier to significantly accelerate research and the availability of therapeutic solutions to patients who suffer from Parkinson’s disease and related neurodegenerative disorders. “


The group led by Prof Ventura has a long experience in the study of protein misfolding and aggregation and their connection with neurodegenerative diseases, with a particular focus on the development of innovative therapeutics for these pathologies. They have developed a methodology that allows identifying candidates targeting α-synuclein among thousands of chemical compounds. “The collaboration with Servier will allow us to join efforts in the search and development of a molecule which can be used for the treatment and, hopefully, the prevention of Parkinson’s disease” pointed out Prof Ventura.


Parkinson’s disease is the second most common neurodegenerative disease, after Alzheimer disease, and affects about 10 million people worldwide[1]. Parkinson’s disease is caused by the progressive degeneration – or even disappearance – of neurons, in particular in the area of the brain specifically responsible for the production of dopamine, a neurotransmitter involved in motor control. Age is the main risk factor for this disease, which targets in particular the ability to perform normal movements. To date, major medical needs for this disease have not been met, as there are no treatments available which have demonstrated a neuroprotective or neuroregenerative effect.



About Institute of Biotechnology and Biomedicine (IBB)

The Institute of Biotechnology and Biomedicine (IBB) was created in 1970 as a research institute of the Universi¬tat Autònoma de Barcelona (UAB). The over 200 researchers currently working at the IBB conduct top-level scientific research with the aim of advancing scientific findings into translational results, to revert the knowledge to society.


The IBB hosts 18 research groups organised into 3 programmes covering different areas of scientific expertise that include bioinfor¬matics, cellular and structural biology, genomics, immu¬nology, microbiology and proteomics. Their resear¬chers participate in high competitive calls, both national and internationally, aimed at funding basic and translatio¬nal research.


More information: https://ibb.uab.cat/


[1] Parkinson’s Foundation – https://www.parkinson.org/Understanding-Parkinsons/Statistics

Press release

Last press release

Press release
Servier appoints Angelo Paci as Oncology & Immuno-Oncology Program Leader
Press release
Servier appoints Nicolas Lévy as Chief Scientist Rare Diseases
Press release
Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology